What question did this study set out to answer?

July 8, 2026British Journal of Haematology

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myeloma

View Full Paper

Ask AI

Bookmark

Authors

CMCurtis MarcouxDalhousie University DMDenái R. MiltonThe University of Texas MD Anderson Cancer Center MTMark R. TannerThe University of Texas MD Anderson Cancer Center

Discussion

Member takes

Implication

Retrospective analysis reveals KRd induction leads to deeper responses and improved PFS in newly diagnosed multiple myeloma patients, implying better outcomes.

Key Points

To compare the effectiveness of carfilzomib, lenalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in treating newly diagnosed multiple myeloma before stem cell transplant.
Retrospective analysis of 1129 patients with NDMM receiving KRd (n=364) or VRd (n=765) before stem cell transplantation.
Evaluation of pretransplant complete response rates and post-transplant outcomes.
Utilized inverse probability-weighted multivariable analysis for progression-free survival.
KRd led to higher pretransplant complete response rates (23% vs. 16%; p=0.002) than VRd.
Median progression-free survival for KRd was 62.2 months compared to 48.7 months for VRd (HR 0.74 [0.59-0.93], p=0.009).
No significant difference in overall survival between KRd and VRd (not reached vs. 122.7 months; HR 0.86 [0.59-1.25], p=0.43).

Cite This Study

Marcoux et al. (2026) studied this question.

synapsesocial.com/papers/6a4de9add2ea289ef6283c90 https://doi.org/10.1111/bjh.70642

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis reveals KRd induction leads to deeper responses and improved PFS in newly diagnosed multiple myeloma patients, implying better outcomes.

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myeloma

Discussion

Member takes

Implication

Key Points

Cite This Study

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myeloma

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider